# Title

 Food and Drugs. PART 250â€”SPECIAL REQUIREMENTS FOR SPECIFIC HUMAN DRUGS


# ID

 CFR-2018-title21-vol4.Pt. 250


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                          |
|:------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['within', 'before', 'prior to', 'after', 'more than']                                                                                                                                                          |
| Duration    | ['30.0 day', '60.0 day', '90.0 day']                                                                                                                                                                            |
| Condition   | ['subject to', 'until', 'where', 'when', 'unless', 'if', 'unless and until']                                                                                                                                    |
| Entities    | ['Pernicious', 'Amyl', 'United States', 'Such', 'Amphetamine', 'Severe', 'United States Pharmacopeia', 'Avoid', 'Misuse', 'Food', 'Parenteral', 'Hexachlorophene', 'Stramonium', 'Human', 'Drug', 'Experience'] |
| Date        | ['1972-10-27', '1978-01-31', '1972-12-26', '1960-10-01', '1972-09-27', '1972-04-04', '1967-08-25', '1972-05-11', '1969-07-01']                                                                                  |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                               |
|:--------------|:----------------------------------------------------------------------------------------------------------------------|
| within        | to established hypothyroidism are regarded as new drugs within the meaning of section 201(p) of the Federal           |
| after         | dispensing of stramonium preparations contrary to this statement after 60 days following the date of its publication  |
| within        | regarded as misbranded unless the labeling on or within the package from which the drug is to                         |
| after         | this statement of policy if such act occurs after  July 1, 1969.                                                      |
| after         | the post coronary state, except angina pectoris present after  coronary occlusion and myocardial infarction.          |
| before        | new drug that requires an approved new-drug application before  marketing.                                            |
| more than     | use in self-medication are aqueous solutions containing not more than  0.04 percent potassium permanganate.           |
| prior to      | be regarded as misbranded if at any time prior to dispensing the label fails to bear the statement                    |
| more than     | for veterinary use if such drug contains not more than 50 percent of potassium permanganate and includes other        |
| more than     | (i) It is an aqueous solution containing not more than  0.04 percent potassium permanganate.                          |
| within        | any potassium permanganate preparations intended for drug use within the jurisdiction of the Federal Food, Drug, and  |
| after         | Drug, and Cosmetic Act contrary to this statement after 60 days from the date of its publication                      |
| within        | for the availability of such oral preparations, standardized within the meaning of the broad limits characteristic of |
| within        | intrinsic factor concentrate will be regarded as misbranded within the meaning of section 503(b) of the Federal       |
| within        | intrinsic factor concentrate will be regarded as adulterated within  the meaning of section 402(a)(2)(C) of the act.  |
| within        | be initiated with respect to any article shipped within the jurisdiction of the act contrary to the                   |
| after         | contrary to the provisions of this policy statement after the 180th day following publication of this statement       |
| within        | statement &#8220;Rx only,&#8221; and the labeling on or within the package from which the drug is to                  |
| within        | that products containing hexachlorophene may appropriately be used within  clearly delineated conditions of use.      |
| after         | first, if all the following conditions were met after September 27, 1972: (i) The product is labeled                  |
| within        | for the revised label and full disclosure labeling. within                                                            |
| within        | formulation where appropriate to comply with this order. within                                                       |
| within        | a part of the new drug application file. within                                                                       |
| within        | obtained from use of the drug as recommended. within                                                                  |
| within        | approved new drug application, which must be submitted within the time set out in paragraph (c)(4) of                 |
| prior to      | such ingredients, shall be adequately tested for safety prior to  marketing.                                          |
| prior to      | or product whose safety is not adequately substantiated prior to marketing may be adulterated and will in any         |
| within        | Shipments of products falling  within the scope of paragraphs (c), (d), or (e)                                        |
| after         | herein shall be the subject of regulatory proceedings after  the effective date of the final order.                   |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                     |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 60.0 day   | (d) The labeling or dispensing of stramonium preparations contrary to this statement after 60 days following the date of its publication in the Federal Register may be made the subject of regulatory proceedings.                                                                                                         |
| 60.0 day   | (d) The labeling or dispensing of any potassium permanganate preparations intended for drug use within the jurisdiction of the Federal Food, Drug, and Cosmetic Act contrary to this statement after 60 days from the date of its publication in the Federal Register may be made the subject of regulatory proceedings.    |
| 30.0 day   | (ii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for the revised label and full disclosure labeling.                                                                                                                                                    |
| 30.0 day   | (iii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for a revised formulation where appropriate to comply with this order.                                                                                                                                |
| 90.0 day   | (iv) Within 90 days, or by (12-26-72) the holder of an approved new drug application submits a supplement containing blood level data obtained from use of the drug as recommended, unless such information is a part of the new drug application file.                                                                     |
| 90.0 day   | (v) Within 90 days, or by (12-26-72), the manufacturer or distributor of such a drug for which a new drug approval is not in effect submits a new drug application in accord with &#167;&#8201;314.50 of the new drug regulations (21 CFR 314.50), including blood level data obtained from use of the drug as recommended. |


## Condition

| Condition        | Context                                                                                                                          |
|:-----------------|:---------------------------------------------------------------------------------------------------------------------------------|
| where            | rationale except possibly in those relatively uncommon instances where the condition is directly related to hypothyroidism and   |
| when             | system stimulants with or without other drug substances when offered for or as adjuncts to the treatment,                        |
| when             | Such combinations  when offered for obesity in humans directly attributable to                                                   |
| subject to       | Drug Administration showing that such products have been subject to abuse and misuse on a fairly large scale,                    |
| if               | of other ingredients, will be regarded as misbranded if they are labeled with directions for use in                              |
| unless           | amyl nitrite inhalant will be regarded as misbranded unless the labeling on or within the package from                           |
| if               | or dispensed contrary to this statement of policy if  such act occurs after July 1, 1969.                                        |
| subject to       | the Food and Drug Administration as misbranded and subject to regulatory proceedings, unless such recommendations are covered by |
| unless           | Administration as misbranded and subject to regulatory proceedings, unless such recommendations are covered by the approval of   |
| if               | of the Federal Food, Drug, and Cosmetic Act if its label fails to bear in a prominent                                            |
| subject to       | permanganate tablets intended for human use are drugs subject to section 503(b)(1) of the Federal Food, Drug, and                |
| if               | Such drugs will be regarded as misbranded  if at any time prior to dispensing the label                                          |
| unless           | of this chapter will be regarded as misbranded unless  the label bears the statement, &#8220;Rx only.&#8221;                     |
| when             | (3) These drugs will be regarded as misbranded  when intended for veterinary use unless the label bears                          |
| unless           | regarded as misbranded when intended for veterinary use unless the label bears the legend, &#8220;Caution: Federal law           |
| if               | a drug labeled and marketed for veterinary use if such drug contains not more than 50 percent                                    |
| unless           | and (2) and section 502(j) of the act unless , among other things, all of the following                                          |
| unless           | of the Federal Food, Drug, and Cosmetic Act unless  it is labeled with the statement &#8220;Rx only.&#8221;                      |
| unless           | sections 502 (f)(2) and (j) of the act unless its labeling bears a statement to the effect                                       |
| unless and until | This statement of policy will remain in effect  unless and until replaced by a monograph resulting from the OTC                  |
| subject to       | containing drugs will be regarded as misbranded and subject to regulatory proceedings unless the label bears the statement       |
| unless           | regarded as misbranded and subject to regulatory proceedings unless the label bears the statement &#8220;Rx only,&#8221; and     |
| until            | new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued                 |
| until            | new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued                 |
| if               | or until January 31, 1978, whichever comes first, if all the following conditions were met after September                       |
| where            | a supplement to provide for a revised formulation where  appropriate to comply with this order.                                  |
| unless           | obtained from use of the drug as recommended, unless such information is a part of the new                                       |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                   |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                   |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                   |
| where            | use of hexachlorophene shall be limited to situations where an alternative preservative has not yet been shown                   |
| unless           | and will in any event be deemed misbranded unless it contains a conspicuous front panel statement that                           |
| where            | hexachlorophene content on the labeling of the products, where  required, shall be on a w/w basis.                               |


## Entities

| Entities                   | Context                                                                                                                        |
|:---------------------------|:-------------------------------------------------------------------------------------------------------------------------------|
| Food                       | Food  and Drugs.                                                                                                               |
| Food                       | The Commissioner of  Food and Drugs finds that the administration of such                                                      |
| Food                       | In particular, the Commissioner of  Food and Drugs finds that neither the consensus of                                         |
| Stramonium                 | Stramonium preparations labeled with directions for use in self-medication                                                     |
| Misuse                     | Misuse of stramonium preparations can cause serious toxic effects                                                              |
| Food                       | the basis of this information, the Commissioner of Food and Drugs has concluded that such articles have                        |
| Amyl                       | Amyl nitrite inhalant as a prescription drug for human                                                                         |
| Food                       | 25, 1967 (32 FR 12404), the Commissioner of Food and Drugs received reports of the abuse of                                    |
| Food                       | it is the opinion of the Commissioner of Food  and Drugs, concurred in by the                                                  |
| Amphetamine                | Amphetamine  and methamphetamine inhalers regarded as prescription drugs.                                                      |
| Food                       | physicians, parents, and others as well as from Food and Drug Administration investigations, it is evident that                |
| Amphetamine                | Amphetamine tablets and amphetamine inhalers have been restricted to                                                           |
| Drug                       | is the considered opinion of the Food and Drug Administration that, in order to adequately protect the                         |
| Experience                 | Experience with these cases shows that such use of                                                                             |
| Severe                     | Severe injury may result from use internally or as                                                                             |
| Avoid                      | Avoid  contact with mucous membranes.&#8221;                                                                                   |
| United States Pharmacopeia | of the Anti-anemia Preparations Advisory Board of the United States Pharmacopeia is concerned with the status of the treatment |
| United States              | The Sixteenth Revision of the Pharmacopeia of the United States , which became official on October 1, 1960,                    |
| Food                       | pertinent information from other sources, the Commissioner of Food and Drugs finds it is the consensus of                      |
| Parenteral                 | Parenteral cyanocobalamin preparations have not been and are not                                                               |
| Pernicious                 | Pernicious anemia is a disease that is associated, among                                                                       |
| Hexachlorophene            | Hexachlorophene , as a component of drug and cosmetic                                                                          |
| Human                      | Human toxicity reports include data on symptomatology, blood and                                                               |
| Such                       | Such use of hexachlorophene shall be limited to situations                                                                     |
| Hexachlorophene            | Hexachlorophene may be used as a preservative in cosmetic                                                                      |
| Such                       | Such use of hexachlorophene shall be limited to situations                                                                     |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1967-08-25 | As a result of a proposed policy statement published August 25, 1967 (32 FR 12404), the Commissioner of Food and Drugs received reports of the abuse of this drug by those who do not require it for medical purposes.                                                                                                                                                                                                                                                                                                   |
| 1969-07-01 | (b) Therefore, amyl nitrite inhalant will be regarded as misbranded unless the labeling on or within the package from which the drug is to be dispensed bears adequate information for its safe and effective use by physicians, in accordance with &#167;&#8201;201.100(c) of this chapter, and its label bears the statement &#8220;Rx only.&#8221;                                                                                                                                                                    |
|            |                       (c) Regulatory proceedings may be initiated with regard to the interstate shipment of amyl nitrite inhalant that is labeled, advertised, or dispensed contrary to this statement of policy if such act occurs after July 1, 1969.                                                                                                                                                                                                                                                                  |
| 1960-10-01 | It clearly presents the following facts:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |                       (1) The Sixteenth Revision of the Pharmacopeia of the United States, which became official on October 1, 1960, does not include preparations intended for the treatment of pernicious anemia by oral administration.                                                                                                                                                                                                                                                                               |
| 1972-04-04 | A notice published in the Federal Register of April 4, 1972 (37 FR 6775), invited data on OTC antimicrobial ingredients, including hexachlorophene, for review by an OTC Drug Advisory Review Panel to be convened under the procedures set forth in the Federal Register of May 11, 1972 (37 FR 9464).                                                                                                                                                                                                                  |
| 1972-05-11 | A notice published in the Federal Register of April 4, 1972 (37 FR 6775), invited data on OTC antimicrobial ingredients, including hexachlorophene, for review by an OTC Drug Advisory Review Panel to be convened under the procedures set forth in the Federal Register of May 11, 1972 (37 FR 9464).                                                                                                                                                                                                                  |
| 1978-01-31 | (4) Marketing of products for the indications listed in paragraph (c)(3) of this section may be continued without an approved new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued on a proposal by the Director of the Center for Drug Evaluation and Research to refuse to approve such new drug application (or required supplement) or until January 31, 1978, whichever comes first, if all the following conditions were met after September 27, 1972: |
|            |                       (i) The product is labeled with the statement &#8220;Rx only&#8221; and adequate information for safe and effective use as set forth in paragraph (c)(3) of this section.                                                                                                                                                                                                                                                                                                                          |
| 1972-09-27 | (4) Marketing of products for the indications listed in paragraph (c)(3) of this section may be continued without an approved new drug application (or required supplement thereto) either until a notice of opportunity for hearing is issued on a proposal by the Director of the Center for Drug Evaluation and Research to refuse to approve such new drug application (or required supplement) or until January 31, 1978, whichever comes first, if all the following conditions were met after September 27, 1972: |
|            |                       (i) The product is labeled with the statement &#8220;Rx only&#8221; and adequate information for safe and effective use as set forth in paragraph (c)(3) of this section.                                                                                                                                                                                                                                                                                                                          |
| 1972-10-27 | (ii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for the revised label and full disclosure labeling.                                                                                                                                                                                                                                                                                                                                                 |
| 1972-10-27 | (iii) Within 30 days, or by (10-27-72) the holder of an approved new drug application submits a supplement to provide for a revised formulation where appropriate to comply with this order.                                                                                                                                                                                                                                                                                                                             |
| 1972-12-26 | (iv) Within 90 days, or by (12-26-72) the holder of an approved new drug application submits a supplement containing blood level data obtained from use of the drug as recommended, unless such information is a part of the new drug application file.                                                                                                                                                                                                                                                                  |
| 1972-12-26 | (v) Within 90 days, or by (12-26-72), the manufacturer or distributor of such a drug for which a new drug approval is not in effect submits a new drug application in accord with &#167;&#8201;314.50 of the new drug regulations (21 CFR 314.50), including blood level data obtained from use of the drug as recommended.                                                                                                                                                                                              |


